Safely Converting an Entire Academic Medical Center From Sliding Scale to Basal Bolus Insulin via Implementation of the eGlycemic Management System. (January 2018)

• Record Type: Journal Article
• Authors: Newsom, Rosalina; Patty, Christopher; Camarena, Emma; Sawyer, Regina; McFarland, Raymie; Gray, Thomas; Mabrey, Melanie
• Is Part Of: Journal of diabetes science and technology. Volume 12:Number 1(2018:Jan.)
• Page Start: 53
• Page End: 59
• Publication Date: 2018-01
• Subjects: computerized insulin algorithm -- diabetes -- Glucommander -- glycemic management -- hypoglycemia -- sliding scale -- basal bolus -- insulin IV -- subcutaneous insulin -- length of stay -- electronic glycemia management; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/1932296817747619
• Languages: English
• ISSNs: 1932-2968

Abstract

Objective: Hyperglycemia is common in the inpatient setting and providers frequently rely on sliding scale insulin. This case study reviews the experience of one hospital moving from high utilization of sliding scale to basal bolus insulin therapy. Method: This Retrospective Quality Improvement Study describes the journey of clinicians at a 580-bed hospital to convert from high usage of SSI to BBI. Hyperglycemic adult patients prescribed insulin, with/without a diagnosis of diabetes, were included. Results: Data over the first year showed that patients treated with Glucommander (GM) spent more time in the target range of 70-180 mg/dL than patients treated with non-Glucommander (non-GM), with 2, 434 fewer hypoglycemic events and 40, 589 fewer hyperglycemic events. Prior to implementation of GM, SSI was close to 95%, BBI at 5%. Within the first month of use, 96% usage of BBI was achieved. Reduction of hypoglycemic events (% of BG < 70 mg/dL) by 21% with 2.16% non-GM compared to GM at 1.74% and severe Hypoglycemia (% of BG < 50 mg/dL) by 50% in the ICU 3% non-GM compared to GM at 1.5%. In addition, patients treated with GM had a shorter LOS than patients treated with non-GM by 3.18 days and used 47.4% less point of care tests per patient. Conclusion: Glycemic management improved with use of eGMS. The conversion from SSI to BBI enhanced overall patient safety, eliminated the time and effort otherwise required when manually titrating insulin and reduced overall cost of care for patients on insulin therapy.